免疫性血小板减少症 中国就医指南

Immune Thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by isolated low platelet counts (thrombocytopenia) — typically <100 × 10⁹/L — in the absence of other causes such as malignancy, infection, or drug exposure. In ITP, the immune system mistakenly produces autoantibodies (most commonly IgG targeting glycoprotein IIb/IIIa or Ib/IX on platelet surfaces), leading to premature platelet destruction by Fc receptor–bearing macrophages in the spleen and impaired megakaryocyte maturation in the bone marrow. This dual mechanism — peripheral destruction and central production failure — underpins the pathophysiology. Primary ITP is idiopathic; secondary forms may accompany systemic lupus erythematosus, chronic lymphocytic leukemia, HIV, or H. pylori infection. Epidemiologically, ITP has a bimodal incidence: children (often post-viral, acute, self-limiting) peak at ages 2–6 years, while adults show a steady rise after age 40, with female predominance (F:M ≈ 2–3:1). The overall incidence is approximately 3.3 per 100,000 person-years in adults and 5.3 per 100,000 in children; prevalence in adults is estimated at 9–10 per 100,000. Key risk factors include female sex, age >60 years, autoimmune comorbidities (e.g., thyroid disease, rheumatoid arthritis), and certain infections (e.g., H. pylori, hepatitis C, HIV). While many patients are asymptomatic, clinical manifestations range from mild mucocutaneous bleeding (petechiae, purpura, epistaxis, menorrhagia) to life-threatening intracranial hemorrhage (<1% of cases but highest cause of ITP-related mortality). Fatigue — often disproportionate to platelet count — is reported by up to 70% of adult patients and significantly impairs physical functioning, work productivity, and emotional well-being. Anxiety about bleeding, treatment side effects (e.g., corticosteroid-induced insomnia or weight gain), and diagnostic uncertainty contribute substantially to reduced health-related quality of life (HRQoL). Patients frequently report limitations in daily activities, social engagement, and exercise tolerance. Chronic ITP (persisting >12 months) affects ~20–30% of adults and carries higher cumulative treatment burden and psychosocial morbidity. Early diagnosis requires careful exclusion of mimics (e.g., drug-induced thrombocytopenia, myelodysplastic syndromes, TTP) via comprehensive history, physical exam, complete blood count with peripheral smear, and often bone marrow evaluation in atypical cases. Management goals focus not solely on platelet count normalization but on preventing clinically significant bleeding while minimizing treatment toxicity and preserving long-term HRQoL.

# 免疫性血小板减少症（ITP）治疗方案与费用明细（血液科）

一、非手术/保守治疗方案

• •一线药物治疗（初治、PLT ≥20×10⁹/L无出血）：口服泼尼松（0.5–1.0 mg/kg/d，4–6周渐停），费用：80–300元/疗程；含血常规、外周血涂片、肝肾功检查费 260–380元。
• •二线药物（难治/复发/激素依赖）：

- 艾曲泊帕（口服，25–75 mg/d）：4,500–9,000元/月； - 利妥昔单抗（静脉滴注，4次/疗程）：15,000–22,000元/疗程（含输注护理及感染筛查）。

二、手术/介入治疗方案

• •脾切除术（腹腔镜，适用于≥12岁、病程>12个月、药物无效者）：

- 手术+麻醉+住院（7–10天）：32,000–45,000元（含术后血小板监测）。

三、特殊复杂方案

• •重症/危及生命出血（PLT <10×10⁹/L伴黏膜/颅内出血）：

- 血小板输注（紧急支持）：1,200–1,800元/单位（限抢救，不改善自身免疫）。

四、方案快速选择指南

• •预算有限初治患者 → 泼尼松+规范随访（总费用≤5,000元/3个月）；
• •中产家庭/追求长期缓解 → 艾曲泊帕或罗米司亭（年均支出5–12万元）；
• •反复出血/药物失效青少年 → 脾切除术（一次性投入，长期获益率约60–70%）；
• •老年/合并严重并发症者 → IVIG联合小剂量激素，个体化减量维持。